Skip to main content

RH017

WHO Product ID
RH017
Status
Prequalified
INN, dosage form and strength
Levonorgestrel Implant 75mg
Date of prequalification
Basis of listing
Prequalification - Abridged
Therapeutic area
Reproductive health
Type
Finished Pharmaceutical Product
Dosage form
Implant
Reference authority
Finnish Medicines Agency
Applicant organization
Bayer Oy
Pansiontie 47
Turku,
20210
Finland
Packaging details and storage conditions
Packaging Type
Bag, PE/PET/PE
Configuration
Two rods, each containing 75mg levonorgestrel
Shelf life (months)
60
Storage conditions
Do not store above 30°C
API Manufacturing Site(s)
By Organization
By Active Ingredient
Bayer AG
Bergkamen Plant, Ernst Schering Strasse 14
Bergkamen,
59192
Germany
Levonorgestrel
FPP Manufacturing Site(s)
Bayer Oy
Pansiontie 47
Turku,
20210
Finland
WHO Public Assessment Reports


Part 1 - Abstract
Part 2 - All accepted presentations (including photo)
Part 3 - WHO-PQ recommended patient information leaflet*
Part 4 - WHO-PQ recommended summary of product characteristics*
Part 5 - Label
Part 6 - Discussion (status at the time of prequalification)
Part 7 - Steps before Prequalification
Part 8 - Steps following Prequalification (from 01 March 2014, only changes to the published information are included)

* This summary of product characteristics/patient information leaflet focus on uses of the medicine covered by WHO Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities (term to be revised). The medicine may be authorised for additional or different uses by national medicines regulatory authorities. 

Part 1 , Part 2 , Part 3 , Part 4 , Part 5 , Part 7

.